They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February ...

The FBI has turned in a list with 5,000 names of employees who may have worked on Jan. 6, 2021, Capitol riot investigations, ...

The UK Health Security Agency (HSA) today reported another clade 1b mpox case, marking the country's ninth since October 2024 ...

Federal officials today confirmed more H5N1 avian flu outbreaks in poultry in three states, with commercial farms in Missouri ...

In this piece, we will look at the stocks Jim Cramer recently discussed.

1 Gardasil—a vaccine that combats human papillomavirus (HPV)—made $8.6 billion in global sales last year, but this represented a 3% decline over 2023 numbers. "Like many other companies, we've seen ...

It is a cancer that is preventable and highly treatable if people have access to the right kind of medical professionals and ...